Pharmacological interventions for non-ulcer dyspepsia

Area of Science:

• Gastroenterology
• Pharmacology
• Clinical Trials

Background:

• Non-ulcer dyspepsia (NUD) is the most common cause of upper gastrointestinal symptoms, yet its pathophysiology and optimal treatment remain unclear.
• Significant healthcare expenditure is associated with managing dyspepsia, highlighting the need for effective therapeutic strategies.

Purpose of the Study:

• To systematically review the effectiveness of six drug classes in improving dyspepsia and quality of life scores for patients with NUD.
• To compare the efficacy of antacids, histamine H(2) antagonists, proton pump inhibitors, prokinetics, mucosal protecting agents, and antimuscarinics against placebo and each other.

Main Methods:

• A comprehensive search of multiple databases (CENTRAL, MEDLINE, EMBASE, CINAHL, SIGLE) and expert/pharmaceutical company contacts was conducted.
• Inclusion criteria focused on randomized controlled trials (RCTs) comparing the specified drug classes with each other or placebo for NUD.
• Two independent reviewers assessed trial eligibility, quality, and extracted data for analysis.

Main Results:

• Prokinetics (33% RRR), H(2)RAs (23% RRR), and PPIs (13% RRR) demonstrated significantly greater efficacy than placebo in improving NUD symptoms.
• Bismuth salts showed a trend towards superiority over placebo (40% RRR), though not statistically significant.
• Antacids and sucralfate did not show statistically significant benefits over placebo, and potential publication bias was noted for prokinetic efficacy.

Conclusions:

• Anti-secretory therapies, including H(2)RAs and PPIs, show evidence of effectiveness in managing NUD symptoms.
• The interpretation of prokinetic therapy effectiveness is challenging due to potential publication bias.
• Further economic analyses are warranted, emphasizing the need for inexpensive and well-tolerated NUD treatments.